Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant zolbetuximab plus DOS chemotherapy in locally advanced gastric cancer
KCT0010107Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of zolbetuximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Astellas Pharma. Started Apr 2025; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on KCT0010107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010107.